following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
. however, bentley also warned that these treatments can be hazardous as they may cause bleeding which becomes more likely as the amount of svd increases.